Producing Scientific Breakthroughs for the Treatment of Triple Negative Breast Cancer
Battling Triple Negative Breast Cancer is a difficult and painful journey, more so, because there are no effective targeted therapies currently available for its treatment, leaving a gaping void that needs to be addressed with utmost urgency.
We have identified a novel first-in-class drug candidate that directly inhibits our molecular target.
Our Drug Candidate – RDY00120 offers the following benefits:
General Features:
- Directly targets DNA replication/cell proliferation machinery, hence cancer cells cannot find roundabouts.
- Targets a novel molecular target, so we are not in the “me too pool.”
- Will not directly damage the DNA.
- Receptor independent and hence will be an effective therapy for all sub-types of Triple Negative breast cancer.
In-vitro Data for RDY00120: In Triple Negative Breast Cancer Cells
- Selectively targets only the cancer cells, thereby allowing the adjacent normal cells to repair and re-grow
- Inhibits cancer cell viability by 95%
- Causes molecular target protein degradation by 47%
- Causes cancer cell death by necroptosis, hence they cannot re-grow.
- Can be an effective alternate treatment for apoptotic resistant cancer cells.
In-vivo Data for RDY00120: In female mice implanted with Triple Negative Breast Cancer cell xenografts
- Inhibits Tumor Growth Rate (GRI) by 61%.
- Complete Regression in one animal
- No loss in body weight indicating no toxic effects of the drug treatment on animals
- Fewer molecular target positive nuclei in treated versus untreated TNBC tumors